Turzo Sm Bargeen Alam, Hantz Eric R, Lindert Steffen
Department of Chemistry and Biochemistry, Ohio State University, Columbus, OH 43210, USA.
QRB Discov. 2022 Sep 1;3:e14. doi: 10.1017/qrd.2022.12. eCollection 2022.
Machine learning (ML) has revolutionised the field of structure-based drug design (SBDD) in recent years. During the training stage, ML techniques typically analyse large amounts of experimentally determined data to create predictive models in order to inform the drug discovery process. Deep learning (DL) is a subfield of ML, that relies on multiple layers of a neural network to extract significantly more complex patterns from experimental data, and has recently become a popular choice in SBDD. This review provides a thorough summary of the recent DL trends in SBDD with a particular focus on de novo drug design, binding site prediction, and binding affinity prediction of small molecules.
近年来,机器学习(ML)彻底改变了基于结构的药物设计(SBDD)领域。在训练阶段,ML技术通常会分析大量实验确定的数据,以创建预测模型,为药物发现过程提供信息。深度学习(DL)是ML的一个子领域,它依赖于神经网络的多层结构,从实验数据中提取更为复杂的模式,并且最近在SBDD中成为了一种流行的选择。本综述全面总结了SBDD中DL的最新趋势,特别关注小分子的从头药物设计、结合位点预测和结合亲和力预测。